Inhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitro

dc.contributor.buuauthorEgel, Çiğdem
dc.contributor.buuauthorBilaloğlu, Rahmi
dc.contributor.buuauthorAydemir, Nilüfer
dc.contributor.departmentUludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.tr_TR
dc.contributor.orcid0000-0002-3595-6286tr_TR
dc.contributor.researcheridAAH-5296-2021tr_TR
dc.contributor.scopusid6507862539tr_TR
dc.contributor.scopusid6505804122tr_TR
dc.contributor.scopusid26533892300tr_TR
dc.date.accessioned2022-03-14T08:51:40Z
dc.date.available2022-03-14T08:51:40Z
dc.date.issued2002
dc.description.abstractIn this study, the anticlastogenic effects of ascorbic acid and the protective effect of folinic acid against the formation of chromosomal aberrations in humans by pyrimethamine were investigated. Pyrimethamine is a folic acid antagonist used for the treatment of malaria and toxoplasmosis. In this study, 18 different healthy people, who do not drink alcohol and are non-smokers, were chosen as an experimental group; 0.025 mg/ml pyrimethamine was given to the lymphocyte culture, which had been prepared with the peripheral blood taken from this group. After that each of the following doses were given to the same culture: 20, 40, and 80 mM of ascorbic acid and 25, 50, and 100 mM of folinic acid. The results of the cytogenetic evaluation showed that the aberrations due to pyrimethamine in the chromosomes were reduced by ascorbic acid and folinic acid significantly, depending on the given dose.en_US
dc.identifier.citationEgel, Ç. vd. (2002). "Inhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitro". Teratogenesis Carcinogenesis and Mutagenesis, 22(5), 353-362.tr_TR
dc.identifier.endpage362tr_TR
dc.identifier.issn02703211
dc.identifier.issue5tr_TR
dc.identifier.pubmed12210498tr_TR
dc.identifier.scopus2-s2.0-0036025188tr_TR
dc.identifier.startpage353tr_TR
dc.identifier.urihttps://doi.org/10.1002/tcm.10030
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/tcm.10030
dc.identifier.urihttp://hdl.handle.net/11452/24982
dc.identifier.volume22tr_TR
dc.identifier.wos000177779100005tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWiley-Lissen_US
dc.relation.journalTeratogenesis Carcinogenesis and Mutagenesisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnticlastogenen_US
dc.subjectAscorbic aciden_US
dc.subjectChromosomal aberrationen_US
dc.subjectFolinic aciden_US
dc.subjectProtective effecten_US
dc.subjectPyrimethamineen_US
dc.subjectHuman-lymphocyte-culturesen_US
dc.subjectSister-chromatid exchangesen_US
dc.subjectVitamin-Cen_US
dc.subjectFragile sitesen_US
dc.subjectV79 Cellsen_US
dc.subjectIn-vitroen_US
dc.subjectGenotoxicityen_US
dc.subjectInductionen_US
dc.subjectDamageen_US
dc.subjectAgentsen_US
dc.subject.emtreeAscorbic aciden_US
dc.subject.emtreeClastogenen_US
dc.subject.emtreeChromosome aberrationen_US
dc.subject.emtreePyrimethamineen_US
dc.subject.emtreeFolic acid antagonisten_US
dc.subject.emtreeFolinic aciden_US
dc.subject.emtreeToxoplasmosisen_US
dc.subject.emtreeAscorbic aciden_US
dc.subject.emtreeFolic acid antagonisten_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeSmokingen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAlcohol consumptionen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCell protectionen_US
dc.subject.emtreeChromosome aberrationen_US
dc.subject.emtreeCytogeneticsen_US
dc.subject.emtreeDose time effect relationen_US
dc.subject.emtreeLymphocyte cultureen_US
dc.subject.emtreeDose calculationen_US
dc.subject.emtreeDose responseen_US
dc.subject.emtreeEvaluationen_US
dc.subject.emtreeHuman experimenten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeMalariaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNormal humanen_US
dc.subject.emtreeCell cultureen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeMitosisen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshAscorbic aciden_US
dc.subject.meshCells, cultureden_US
dc.subject.meshChromosome aberrationsen_US
dc.subject.meshHumanen_US
dc.subject.meshDose-response relationshipen_US
dc.subject.meshFolic acid antagonistsen_US
dc.subject.meshLeucovorinen_US
dc.subject.meshMitosisen_US
dc.subject.meshPyrimethamineen_US
dc.subject.meshCells, cultureden_US
dc.subject.meshDrugen_US
dc.subject.meshHumansen_US
dc.subject.meshMitosisen_US
dc.subject.scopusHyperpigmentation; Vitamin B 12 Deficiency; Megaloblastic Anemiaen_US
dc.subject.wosOncology genetics & heredityen_US
dc.subject.wosToxicologyen_US
dc.titleInhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitroen_US
dc.typeArticle
dc.wos.quartileQ3 (Toxicology)en_US
dc.wos.quartileQ4en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: